Citius Oncology, Inc. (CTOR) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Citius Oncology, Inc. (CTOR) closed at USD 0.78 on 2026-10-14, a change of -54.9 % over the past year, with a market capitalization of USD 78.9M.

Citius Oncology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Citius Oncology, Inc. key figures

Previous close

USD 0.78 (2026-10-14)

1-year change

-54.9 %

Market cap

USD 78.9M

Enterprise value

USD 72.54M

P/E ratio (trailing)

-1.55

P/E ratio (forward)

n/a

EPS (trailing)

-0.48

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.95

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.86

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Citius Oncology, Inc. and compare it with other stocks.